


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of }
RIECHERS et al. } Art Unit: 1611
Serial No. 08/809,699 } Examiner: Kifle
Filed: March 27, 1997 }
For: NEW CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR
USE

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to Commissioner of
Patents and Trademarks, Washington, D.C.
20231, on: October 6, 1998

Date of Deposit: October 6, 1998

Person Making Deposit: Herb Keil

Signature: Herb Keil October 6, 1998

Date of Signature: October 6, 1998

ZJP
2/6/93
RECEIVED

OCT 13 1998
MATRIX CUSTOMER
SERVICE CENTER

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

SUBMISSION

Sir:

Further to the Claim to Priority ^{OCT 16 1998} mailed in this case on July
24, 1998, attached is a signed ^{verified} English translation of
German 195 33 023.4, filed September 7, 1995.

Respectfully submitted,

KEIL & WEINKAUF

HBK
Herbert B. Keil
Reg. No. 18,967

OCT 13 1998

1101 Connecticut Ave., N.W.
Washington, D.C. 20036
(202) 659-0100

HBK/kas



RECEIVED

OCT 13 1998

MAINTAIN CUSTOMER
SERVICE CENTER

IN THE UNITED STATES PATENT OFFICE

I, Stephen DRANE BSc PhD BDÜ,
translator to RWS Translations Ltd., of Europa House, Marsham
Way, Gerrards Cross, Buckinghamshire, England declare;

1. That I am a citizen of the United Kingdom of Great Britain
and Northern Ireland.

2. That I am well acquainted with the German and English
languages.

3. That the attached is, to the best of my knowledge and
belief, a true translation into the English language of the
accompanying copy of the specification filed with the
application for a patent in Germany on 7 September 1995 under
the number 195 33 023.4 and the official certificate attached
hereto.

4. That I believe that all statements made herein of my own
knowledge are true and that all statements made on information
and belief are true; and further that these statements are made
with the knowledge that wilful false statements and the like so
made are punishable by fine or imprisonment, or both, under
Section 1001 of Title 18 of the United States Code and that such
wilful false statements may jeopardise the validity of the
patent application in the United States of America or any patent
issuing thereon.

A handwritten signature in cursive ink, appearing to read "Stephen Drane".

For and on behalf of RWS Translations Ltd.

The 26th day of February 1998

FEDERAL REPUBLIC OF GERMANY
CERTIFICATE

BASF Aktiengesellschaft

of

67056 Ludwigshafen

have filed a Patent Application under the title:

"Novel carboxylic acid derivatives, their preparation and use"

on 7 September 1995 at the German Patent Office, and declare that they claim, for this application, the inner priority of the Application made in the Federal Republic of Germany on 14 October 1994, File No. P 44 36 851.8.

The attached document is a correct and accurate reproduction of the original submission for this Patent Application.

The German Patent Office has for the time being given the Application the symbols C 07 D 239/60, C 07 D 239/70, C 07 D 403/12, C 07 D 405/12, C 07 D 491/044, C 07 D 487/04, C 07 D 495/04, C 07 D 409/12, C 07 D 413/12, C 07 D 417/12, A 61 K 31/41 and A 61 K 31/505 of the International Patent Classification.

Munich, 16 October 1995
President of the German Patent Office
pp
Nietiedt


File No: 195 33 023.4

We claim:

A carboxylic acid derivative of the formula I

5

10



where R is formyl, tetrazole [sic], nitrile [sic], a COOH group or a radical which can be hydrolyzed to COOH, and the other substituents have the following meanings:

R² hydrogen, hydroxyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio;

X nitrogen or CR¹⁴ where R¹⁴ is hydrogen or C₁₋₅-alkyl, or CR¹⁴ forms together with CR³ a 5- or 6-membered alkylene or alkenylene ring which can be substituted by one or 25 two C₁₋₄-alkyl groups and in which in each case a methylene group can be replaced by oxygen, sulfur, -NH or -NC₁₋₄-alkyl;

R³ hydrogen, hydroxyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, -NH-O-C₁₋₄-alkyl, C₁-C₄-alkylthio or CR³ is 30 linked to CR¹⁴ as indicated above to give a 5- or 6-membered ring;

R⁴ and R⁵ (which can be identical or different):
35 phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, phenoxy, C₁-C₄-alkylthio, amino, C₁-C₄-alkylamino or C₁-C₄-di-40 alkylamino; or

phenyl or naphthyl, which are connected together in the ortho positions via a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO₂, NH or 45 N-alkyl group;

or C₃-C₇-cycloalkyl;

R⁶ hydrogen, C₁-C₈-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl or C₃-C₈-cycloalkyl, where each of these radicals can be substituted one or more times by: halogen, nitro, cyano, C₁-C₄-alkoxy, C₃-C₆-alkenyoxy, C₃-C₆-alkynyoxy, C₁-C₄-alkyl-
5 thio, C₁-C₄-haloalkoxy, C₁-C₄-alkylcarbonyl, C₁-C₄-alkoxy- carbonyl, C₃-C₈-alkylcarbonylalkyl, C₁-C₄-alkylamino, di-C₁-C₄-alkylamino, phenyl, or phenyl or phenoxy which is substituted one or more times, eg. one to three times, by halogen, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl,
10 C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio;

phenyl or naphthyl, each of which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy,
15 C₁-C₄-haloalkoxy, phenoxy, C₁-C₄-alkylthio, C₁-C₄-alkylamino, C₁-C₄-dialkylamino, dioxomethylene [sic] or dioxoethylene [sic];

a five- or six-membered heteroaromatic moiety containing one
20 to three nitrogen atoms and/or one sulfur or oxygen atom, which can carry one to four halogen atoms and/or one or two of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl
25 radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio;

30 with the proviso that R⁶ can be hydrogen only when Z is not a single bond;

Y sulfur or oxygen or a single bond;

35 Z sulfur, oxygen, -SO-, -SO₂- or a single bond.

Novel carboxylic acid derivatives, their preparation and use

The present invention relates to novel carboxylic acid derivatives, their preparation and use.


Endothelin is a peptide which is composed of 21 amino acids and is synthesized and released by the vascular endothelium. Endothelin exists in three isoforms, ET-1, ET-2 and ET-3. In the following text, "endothelin" or "ET" signifies one or all isoforms of endothelin. Endothelin is a potent vasoconstrictor and has a potent effect on vessel tone. It is known that this vasoconstriction is caused by binding of endothelin to its receptor (Nature, 332, (1988) 411-415; FEBS Letters, 231, (1988) 440-444 and Biochem. Biophys. Res. Commun., 154, (1988) 868-875).

Increased or abnormal release of endothelin causes persistent vasoconstriction in the peripheral, renal and cerebral blood vessels, which may lead to illnesses. It has been reported in the literature that elevated plasma levels of endothelin were found in patients with hypertension, acute myocardial infarct, pulmonary hypertension, Raynaud's syndrome, atherosclerosis and in the airways of asthmatics (Japan J. Hypertension, 12, (1989) 79, J. Vascular Med. Biology 2, (1990) 207, J. Am. Med. Association 264, (1990) 2868).

Accordingly, substances which specifically inhibit the binding of endothelin to the receptor ought also to antagonize the various abovementioned physiological effects of endothelin and therefore be valuable drugs.

We have found that certain carboxylic acid derivatives are good inhibitors of endothelin receptors.

The invention relates to carboxylic acid derivatives of the formula I



where R is formyl, tetrazole [sic], nitrile [sic], a COOH group or a radical which can be hydrolyzed to COOH, and the other substituents have the following meanings:

5 R² hydrogen, hydroxyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio;

10 X nitrogen or CR¹⁴ where R¹⁴ is hydrogen or C₁-C₅-alkyl, or CR¹⁴ forms together with CR³ a 5- or 6-membered alkylene or alkenylene ring which can be substituted by one or two C₁-C₄-alkyl groups and in which in each case a methylene group can be replaced by oxygen, sulfur, -NH or -NC₁-C₄-alkyl;

15 R³ hydrogen, hydroxyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, -NH-O-C₁-C₄-alkyl, C₁-C₄-alkylthio or CR³ is linked to CR¹⁴ as indicated above to give a 5- or 6-membered ring;

20 R⁴ and R⁵ (which can be identical or different):

25 phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, phenoxy, C₁-C₄-alkylthio, amino, C₁-C₄-alkylamino or C₁-C₄-di-alkylamino; or

30 phenyl or naphthyl, which are connected together in the ortho positions via a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO₂-, NH- or N-alkyl group, or C₃-C₇-cycloalkyl;

35 R⁶ hydrogen, C₁-C₈-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl or C₃-C₈-cycloalkyl, where each of these radicals can be substituted one or more times by: halogen, nitro, cyano, C₁-C₄-alkoxy, C₃-C₆-alkenyoxy, C₃-C₆-alkynyoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkoxy, C₁-C₄-alkylcarbonyl, C₁-C₄-alkoxy-carbonyl, C₃-C₈-alkylcarbonylalkyl, C₁-C₄-alkylamino, di-C₁-C₄-alkylamino, phenyl, or phenyl or phenoxy which is substituted one or more times, e.g. one to three times, by halogen, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio;

40 phenyl or naphthyl, each of which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy,

45 phenyl or naphthyl, each of which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy,

C_1-C_4 -haloalkoxy, phenoxy, C_1-C_4 -alkylthio, C_1-C_4 -alkylamino, C_1-C_4 -dialkylamino, dioxomethylene [sic] or dioxoethylene [sic];

5 a five- or six-membered heteroaromatic moiety containing one to three nitrogen atoms and/or one sulfur or oxygen atom, which can carry one to four halogen atoms and/or one or two of the following radicals: C_1-C_4 -alkyl, C_1-C_4 -haloalkyl, C_1-C_4 -alkoxy, C_1-C_4 -haloalkoxy, C_1-C_4 -alkylthio, phenyl, 10 phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C_1-C_4 -alkyl, C_1-C_4 -haloalkyl, C_1-C_4 -alkoxy, C_1-C_4 -haloalkoxy and/or C_1-C_4 -alkylthio;

15 with the proviso that R^6 can be hydrogen only when Z is not a single bond;

Y sulfur or oxygen or a single bond;


20 Z sulfur or oxygen or a single bond.

The compounds, and the intermediates for preparing them, such as IV and VI, may have one or more asymmetrical [sic] substituted 25 carbon atoms. Such compounds may be in the form of the pure enantiomers or pure diastereomers or a mixture thereof. The use of an enantioselectively pure compound as active substance is preferred.

The invention furthermore relates to the use of the abovementioned carboxylic acid derivatives for producing drugs, in particular for producing endothelin receptor inhibitors.


The invention furthermore relates to the preparation of the compounds of the formula IV in enantiomerically pure form. Enantioselective epoxidation of an olefin with two phenyl substituents is known (J. Org. Chem. 59, 1994, 4378-4380). We have now found, surprisingly, that even ester groups in these systems permit epoxidation in high optical purity.

40 The preparation of the compounds according to the invention where Z is sulfur or oxygen starts from the epoxides IV, which are obtained in a conventional manner, e.g. as described in J. March, Advanced Organic Chemistry, 2nd ed., 1983, page 862 and page 750, from the ketones II or the olefins III:



15 Carboxylic acid derivatives of the general formula VI can be prepared by reacting the epoxides of the general formula IV (eg. with $R = ROOR^{10}$ [sic]) with alcohols or thiols of the general formula V where R^6 and Z have the meanings stated in claim 1.

20



To do this, compounds of the general formula IV are heated with compounds of the formula V, in the molar ratio of about 1:1 to 1:7, preferably 1 to 3 mole equivalents, to 50-200°C, preferably 80-150°C.

30

The reaction can also take place in the presence of a diluent. All solvents which are inert toward the reagents used can be used for this purpose.

35 Examples of such solvents or diluents are water, aliphatic, ali-cyclic and aromatic hydrocarbons, which may in each case be chlo-riinated, such as hexane, cyclohexane, petroleum ether, naphtha, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichloroethylene, ethers such 40 as diisopropyl ether, dibutyl ether, methyl tert-butyl ether, propylene oxide, dioxane and tetrahydrofuran, ketones such as acetone, methyl ethyl ketone, methyl isopropyl ketone and methyl isobutyl ketone, nitriles such as acetonitrile and propionitrile, alcohols, such as methanol, ethanol, isopropanol, butanol and 45 ethylene glycol, esters such as ethyl acetate and amyl acetate, amides such as dimethylformamide, dimethylacetamide and N-methyl-pyrrolidone, sulfoxides and sulfones, such as dimethyl sulfoxide

and sulfolane, bases such as pyridine, cyclic ureas such as 1,3-dimethylimidazolidin-2-one and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone.

5 The reaction is preferably carried out at a temperature in the range from 0°C to the boiling point of the solvent or mixture of solvents.

10 The presence of a catalyst may be advantageous. Suitable catalysts are strong organic and inorganic acids, and Lewis acids. Examples thereof are, inter alia, sulfuric acid, hydrochloric acid, trifluoroacetic acid, p-toluenesulfonic acid, boron trifluoride etherate and titanium(IV) alcoholates.

15 Compounds of the formula VI where R⁴ and R⁵ are cycloalkyl can also be prepared by subjecting compounds of the formula VI where R⁴ and R⁵ are phenyl, naphthyl, or phenyl or naphthyl substituted as described above, to a nuclear hydrogenation.

20 Compounds of the formula VI can be obtained in enantiomerically pure form by starting from enantiomerically pure compounds of the formula IV and reacting them in the manner described with compounds of the formula V.


25 It is furthermore possible to obtain enantiomerically pure compounds of the formula VI by carrying out a classical racemate resolution on racemic or diastereomeric compounds of the formula VI using suitable enantiomerically pure bases such as brucine, strychnine, quinine, quinidine, chinchonidine [sic], chinchonine

30 [sic], yohimbine, morphine, dehydroabietylamine, ephedrine (-), (+), deoxyephedrine (+), (-), threo-2-amino-1-(p-nitrophenyl)-1,3-propanediol (+), (-), threo-2-(N,N-dimethylamino)-1-(p-nitrophenyl)-1,3-propanediol (+), (-) threo-2-amino-1-phenyl-1,3-propanediol (+), (-), α-methylbenzylamine (+), (-),

35 α-(1-naphthyl)ethylamine (+), (-), α-(2-naphthyl)ethylamine (+), (-), aminomethylpinane, N,N-dimethyl-1-phenylethylamine, N-methyl-1-phenylethylamine, 4-nitrophenylethylamine, pseudoephedrine, norephedrine, norpseudoephedrine, amino acid derivatives, peptide derivatives.

40

The compounds according to the invention where Y is oxygen, and the remaining substituents have the meanings stated under the general formula I, can be prepared, for example, by reacting the carboxylic acid derivatives of the general formula VI where the 45 substituents have the stated meanings with compounds of the general formula VII



10


where R^{15} is halogen or $R^{16}-SO_2-$, where R^{16} can be C_1-C_4 -alkyl, C_1-C_4 -haloalkyl or phenyl. The reaction preferably takes place in one of the abovementioned inert diluents with the addition of a suitable base, ie. of a base which deprotonates the intermediate 15 VI, in a temperature range from room temperature to the boiling point of the solvent.

Compounds of the formula VII are known, some of them can be bought, or they can be prepared in a generally known manner.

20

It is possible to use as base an alkali metal or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride, a carbonate such as an alkali metal carbonate, eg. sodium or potassium carbonate, an alkali metal or alkaline earth metal hydroxide such as sodium or potassium hydroxide, an organometallic compound such as butyllithium, or an alkali metal amide such as lithium diisopropylamide.

The compounds according to the invention where Y is sulfur, and
30 the remaining substituents have the meanings stated under the
general formula I, can be prepared, for example, by reacting car-
boxylic acid derivatives of the general formula VIII, which can
be obtained in a known manner from compounds of the general for-
35 mula VI and in which the substituents have the abovementioned
meanings, with compounds of the general formula IX, where R^2 , R^3
and X have the meanings stated under general formula I.




The reaction preferably takes place in one of the abovementioned inert diluents with the addition of a suitable base, ie. a base which deprotonates the intermediate IX, in a temperature range from room temperature to the boiling point of the solvent.

5

It is possible to use as base, besides those mentioned above, organic bases such as triethylamine, pyridine, imidazole or diaza-bicycloundecane [sic].

10 Carboxylic acid derivatives of the formula VIa (Z in formula VI = direct linkage) can be prepared by reacting epoxides of the formula IV with cuprates of the formula XI:

15



20

XI

VIa

The cuprates can be prepared as described in *Tetrahedron Letters* 23, (1982) 3755.

25

Compounds of the formula I can also be prepared by starting from the corresponding carboxylic acids, ie. compounds of the formula I where R is COOH, and initially converting these in a conventional manner into an activated form, such as a halide, an anhydride or imidazolide, and then reacting the latter with an appropriate hydroxy compound HOR¹⁰. This reaction can be carried out in the usual solvents and often requires addition of a base, in which case those mentioned above are suitable. These two steps can also be simplified, for example, by allowing the carboxylic acid to act on the hydroxy compound in the presence of a dehydrating agent such as a carbodiimide.

In addition, it is also possible for compounds of the formula I to be prepared by starting from the salts of the corresponding 40 carboxylic acids, ie. from compounds of the formula I where R is COR¹ and R¹ is OM, where M can be an alkali metal cation or the equivalent of an alkaline earth metal cation. These salts can be reacted with many compounds of the formula R¹-A where A is a conventional nucleofugic leaving group, for example halogen such as 45 chlorine, bromine, iodine or aryl- or alkylsulfonyl which is unsubstituted or substituted by halogen, alkyl or haloalkyl, such as toluenesulfonyl and methylsulfonyl, or another equivalent

leaving group. Compounds of the formula R¹-A with a reactive substituent A are known or can be easily obtained with general expert knowledge. This reaction can be carried out in conventional solvents and advantageously takes place with the addition of a base, in which case those mentioned above are suitable.

The radical R in formula I may vary widely. For example, R is a group

10



15 where R¹ has the following meanings:

- a) hydrogen;
- b) succinylimidoxy [sic];
- 20 c) a five-membered heteroaromatic moiety linked by a nitrogen atom, such as pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which may carry one or two halogen atoms, in particular fluorine and chlorine and/or one or two of the following radicals:

C₁-C₄-alkyl such as methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl, 2-butyl;

30 C₁-C₄-haloalkyl, in particular C₁-C₂-haloalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl;

35 C₁-C₄-haloalkoxy, in particular C₁-C₂-haloalkoxy such as difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-1,1,2-trifluoroethoxy and pentafluoroethoxy, in particular trifluoromethoxy;

40 C₁-C₄-alkoxy such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, in particular methoxy, ethoxy, 1-methylethoxy;


9

C_1-C_4 -alkylthio such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-dimethylethylthio, in particular methylthio and ethylthio;

5

d) R^1 furthermore a radical

10



where m is 0 or 1 and R^7 and R^8 , which can be identical or different, have the following meanings:

15

hydrogen

C_1-C_8 -alkyl, in particular C_1-C_4 -alkyl as mentioned above;

20

C_3-C_6 -alkenyl such as 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-

25

2-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dime-

30

thyl-3-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl and 1-ethyl-2-methyl-2-propenyl, in particular 2-propenyl, 2-butenyl, 3-methyl-2-butenyl and 3-methyl-2-pentenyl;

40

C_3-C_6 -alkynyl such as 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1-methyl-2-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl,

45

1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4-pentynyl,

10

4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl,
1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl,
2,2-dimethyl-3-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl,
2-ethyl-3-butynyl and 1-ethyl-1-methyl-2-propynyl, preferably
5 2-propynyl, 2-butynyl, 1-methyl-2-propynyl and
1-methyl-2-butynyl, in particular 2-propynyl

C₃-C₈-cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl,
10 cyclohexyl and cycloheptyl, cyclooctyl, where these alkyl,
cycloalkyl, alkenyl and alkynyl groups can each carry one to
five halogen atoms, in particular fluorine or chlorine and/or
one or two of the following groups:

C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkoxy as
15 mentioned above, C₃-C₆-alkenyloxy, C₃-C₆-alkenylthio,
C₃-C₆-alkynyloxy, C₃-C₆-alkynylthio, where the alkenyl and
alkynyl constituents present in these radicals preferably
have the abovementioned meanings;

C₁-C₄-alkylcarbonyl such as, in particular, methylcarbonyl,
10 ethylcarbonyl, propylcarbonyl, 1-methylethylcarbonyl, butyl-
carbonyl, 1-methylpropylcarbonyl, 2-methylpropylcarbonyl,
1,1-dimethylethylcarbonyl;

C₁-C₄-alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl,
25 propyloxycarbonyl, 1-methylethoxycarbonyl, butyloxycarbonyl,
1-methylpropyloxycarbonyl, 2-methylpropyloxycarbonyl,
1,1-dimethylethoxycarbonyl;

C₃-C₆-alkenylcarbonyl, C₃-C₆-alkynylcarbonyl, C₃-C₆-alkenyloxy-
30 carbonyl and C₃-C₆-alkynyloxy carbonyl, where the alkenyl and
alkynyl radicals are preferably defined as detailed above;

phenyl, unsubstituted or substituted one or more times, e.g.
35 one to three times, by halogen, nitro, cyano, C₁-C₄-alkyl,
C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkyl-
thio, such as 2-fluorophenyl, 3-chlorophenyl, 4-bromophenyl,
2-methylphenyl, 3-nitrophenyl, 4-cyanophenyl, 2-trifluoro-
40 methylphenyl, 3-methoxyphenyl, 4-trifluoroethoxyphenyl,
2-methylthiophenyl, 2,4-dichlorophenyl, 2-methoxy-3-methyl-
phenyl, 2,4-dimethoxyphenyl, 2-nitro-5-cyanophenyl,
2,6-difluorophenyl;

11

di-C₁-C₄-alkylamino such as, in particular, dimethylamino, dipropylamino, N-propyl-N-methylamino, N-propyl-N-ethylamino, diisopropylamino, N-isopropyl-N-methylamino, N-isopropyl-N-ethylamino, N-isopropyl-N-propylamino;

5


R⁷ and R⁸ furthermore phenyl which can be substituted by one or more, eg. one to three, of the following radicals: halogen, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio, as mentioned above in particular;

10

or R⁷ and R⁸ together form a C₄-C₇-alkylene chain which is closed to form a ring, is unsubstituted or substituted, eg. substituted by C₁-C₄-alkyl, and may contain a heteroatom

15

selected from the group consisting of oxygen, sulfur or nitrogen, such as -(CH₂)₄-, -(CH₂)₅-, -(CH₂)₆-, -(CH₂)₇-, -(CH₂)₂-O-(CH₂)₂-, -CH₂-S-(CH₂)₃-, -(CH₂)₂-O-(CH₂)₃-, -NH-(CH₂)₃-, -CH₂-NH-(CH₂)₂-, -CH₂-CH=CH-CH₂-, -CH=CH-(CH₂)₃;

20 e) R¹ furthermore a group

25

where k is 0, 1 and 2, p is 1, 2, 3 and 4 and R⁹ is

C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl or unsubstituted or substituted phenyl, as mentioned above in particular.

30

f) R¹ furthermore a radical OR¹⁰, where R¹⁰ is:

hydrogen, the cation of an alkali metal such as lithium, sodium, potassium or the cation of an alkaline earth metal such as calcium, magnesium and barium or an environmentally compatible organic ammonium ion such as tertiary C₁-C₄-alkyl-ammonium or the ammonium ion;

40

C₃-C₈-cycloalkyl as mentioned above, which may carry one to three C₁-C₄-alkyl groups;

45

C₁-C₈-alkyl such as, in particular, methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl,

12

2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl, 2-ethylbutyl, 1-ethyl-2-methylpropyl, which can carry one to five halogen atoms, in particular fluorine and chlorine and/or one of the following radicals:

10 C_1-C_4 -alkoxy, C_1-C_4 -alkylthio, cyano, C_1-C_4 -alkylcarbonyl, C_3-C_8 -cycloalkyl, C_1-C_4 -alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, where the aromatic radicals in turn can carry in each case one to five halogen atoms and/or one to three of the following radicals: nitro, cyano, C_1-C_4 -alkyl, C_1-C_4 -haloalkyl, C_1-C_4 -alkoxy, C_1-C_4 -haloalkoxy and/or C_1-C_4 -alkylthio, as mentioned above in particular;

15 a C_1-C_8 -alkyl as mentioned above, which can carry one to five halogen atoms, in particular fluorine and/or chlorine, and carries one of the following radicals: a 5-membered heteroaromatic moiety containing one to three nitrogen atoms, or a 5-membered heteroaromatic moiety containing a nitrogen atom and an oxygen or sulfur atom, which can carry one to four halogen atoms and/or one or two of the following radicals:

20 25 nitro, cyano, C_1-C_4 -alkyl, C_1-C_4 -haloalkyl, C_1-C_4 -alkoxy, phenyl, C_1-C_4 -haloalkoxy and/or C_1-C_4 -alkylthio. Particular mention may be made of: 1-pyrazolyl, 3-methyl-1-pyrazolyl, 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl,

30 35 4-phenyl-1-pyrazolyl, 4-phenyl-1-pyrazolyl, 4-chloro-1-pyrazolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3-methyl-1,2,4-triazol-1-yl, 5-methyl-1,2,4-triazol-1-yl, 1-benzotriazolyl, 3-isopropyl-5-isoxazolyl, 3-methyl-5-isoxazolyl, 2-oxazolyl, 2-thiazolyl, 2-imidazolyl, 3-ethyl-5-isoxazolyl, 3-phenyl-5-isoxazolyl, 3-tert-butyl-5-isoxazolyl;

40 a C_2-C_6 -alkyl group which carries one of the following radicals in position 2: C_1-C_4 -alkoxyimino, C_3-C_6 -alkynyloxyimino, C_3-C_6 -haloalkenyloxyimino or benzyloxyimino;

45 a C_3-C_6 -alkenyl or C_3-C_6 -alkynyl group, it being possible for these groups in turn to carry one to five halogen atoms; R^{10} furthermore a phenyl radical which can carry one to five halogen atoms and/or one to three of the following radicals: nitro, cyano, C_1-C_4 -alkyl, C_1-C_4 -haloalkyl, C_1-C_4 -alkoxy,

13

C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio, as mentioned above in particular;

5 a 5-membered heteroaromatic moiety which is linked via a nitrogen atom, contains one to three nitrogen atoms and can carry one or two halogen atoms and/or one or two of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, phenyl, C₁-C₄-haloalkoxy and/or C₁-C₄-alkylthio. Particular mention may be made of: 1-pyrazolyl, 3-methyl-1-pyrazolyl, 10 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl, 3-phenyl-1-pyrazolyl, 4-phenyl-1-pyrazolyl, 4-chloro-1-pyrazolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3-methyl-1,2,4-triazol-1-yl, 5-methyl-1,2,4-triazol-1-yl, 1-benzotriazolyl, 15 3,4-dichloro-1-imidazolyl;

R¹⁰ furthermore a group



where R¹¹ and R¹², which can be identical or different, are:


25 C₁-C₈-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl, C₃-C₈-cycloalkyl, it being possible for these radicals to carry a C₁-C₄-alkoxy, C₁-C₄-alkylthio and/or an unsubstituted or substituted phenyl radical, as mentioned above in particular;

30 phenyl which can be substituted by one or more, e.g. one to three, of the following radicals: halogen, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy or C₁-C₄-alkylthio, where these radicals are, in particular, those mentioned above;

35 or R¹¹ and R¹² together form a C₃-C₁₂-alkylene chain which can carry one to three C₁-C₄-alkyl groups and contain a heteroatom from the group consisting of oxygen, sulfur and nitrogen, as mentioned in particular for R⁷ and R⁸.

40 g) R¹ furthermore a radical

14




where R^{13} is:

10 C_1-C_4 -alkyl, C_3-C_6 -alkenyl, C_3-C_6 -alkynyl, C_3-C_8 -cycloalkyl as mentioned above in particular, it being possible for these radicals to carry a C_1-C_4 -alkoxy, C_1-C_4 -alkylthio and/or a phenyl radical as mentioned above;

15 phenyl, unsubstituted or substituted, in particular as mentioned above.

h) R^1 a radical

20



25

where R^{13} has the abovementioned meaning.

R can furthermore be:

30 tetrazole [sic] or nitrile [sic].

In respect of the biological effect, preferred carboxylic acid derivatives of the general formula I, both as pure enantiomers and pure diastereomers or as mixture thereof, are those where the 35 substituents have the following meanings:

40 R^2 hydrogen, hydroxyl, $N(C_1-C_4\text{-alkyl})_2$, the C_1-C_4 -alkyl, C_1-C_4 -haloalkyl, C_1-C_4 -alkoxy, C_1-C_4 -haloalkoxy, C_1-C_4 -alkylthio groups and halogen atoms mentioned in detail for R^1 , especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy;

X nitrogen or CR^{14} where

45 R^{14} is hydrogen or alkyl, or CR^{14} forms together with CR^3 a 4- to 5-membered alkylene or alkenylene ring in which, in each case, a methylene group can be replaced by oxygen or sulfur,

15

such as $-\text{CH}_2-\text{CH}_2-\text{O}-$, $-\text{CH}=\text{CH}-\text{O}-$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{O}-$, $-\text{CH}=\text{CH}-\text{CH}_2\text{O}-$, in particular hydrogen, $-\text{CH}_2-\text{CH}_2-\text{O}-$, $-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{O}-$, $-\text{C}(\text{CH}_3)=\text{C}(\text{CH}_3)-\text{O}-$, $-\text{CH}=\text{C}(\text{CH}_3)-\text{O}-$ or $-\text{C}(\text{CH}_3)=\text{C}(\text{CH}_3)-\text{S}-$;

5 R^3 the hydrogen, hydroxyl, $\text{N}(\text{C}_1\text{-C}_4\text{-alkyl})_2$, $\text{C}_1\text{-C}_4\text{-alkyl}$, $\text{C}_1\text{-C}_4\text{-haloalkyl}$, $\text{C}_1\text{-C}_4\text{-alkoxy}$, $\text{C}_1\text{-C}_4\text{-haloalkoxy}$, $\text{C}_1\text{-C}_4\text{-alkylthio}$ groups and halogen atoms mentioned for R^1 , especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy or is linked to R^{14} as mentioned above to give a 10 5- or 6-membered ring;

15 R^4 and R^5 phenyl or naphthyl, which can be substituted by one or more, eg. one to three, of the following radicals: halogen, nitro, cyano, hydroxyl, mercapto, amino, $\text{C}_1\text{-C}_4\text{-alkyl}$, $\text{C}_1\text{-C}_4\text{-haloalkyl}$, $\text{C}_1\text{-C}_4\text{-alkoxy}$, $\text{C}_1\text{-C}_4\text{-haloalkoxy}$, $\text{C}_1\text{-C}_4\text{-alkylthio}$, $\text{C}_1\text{-C}_4\text{-alkylamino}$, di- $\text{C}_1\text{-C}_4\text{-alkylamino}$, $\text{C}_1\text{-C}_4\text{-alkylcarbonyl}$, $\text{C}_1\text{-C}_4\text{-alkoxycarbonyl}$; phenyl or naphthyl, which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or ethenylene group, 20 an oxygen or sulfur atom or an SO_2 , NH or N-alkyl group, or $\text{C}_3\text{-C}_7\text{-cycloalkyl}$;

25 R^6 $\text{C}_1\text{-C}_8\text{-alkyl}$, $\text{C}_3\text{-C}_6\text{-alkenyl}$, $\text{C}_3\text{-C}_6\text{-alkynyl}$ or $\text{C}_3\text{-C}_8\text{-cycloalkyl}$ as mentioned above in particular, it being possible for these radicals in each case to be substituted one or more times by: halogen, hydroxyl, nitro, cyano, $\text{C}_1\text{-C}_4\text{-alkoxy}$, $\text{C}_3\text{-C}_6\text{-alkenyl-oxy}$, $\text{C}_3\text{-C}_6\text{-alkynylloxy}$, $\text{C}_1\text{-C}_4\text{-alkylthio}$, $\text{C}_1\text{-C}_4\text{-haloalkoxy}$, $\text{C}_1\text{-C}_4\text{-alkylcarbonyl}$, hydroxycarbonyl, $\text{C}_1\text{-C}_4\text{-alkoxycarbonyl}$, $\text{C}_1\text{-C}_4\text{-alkylamino}$, di- $\text{C}_1\text{-C}_4\text{-alkylamino}$ or unsubstituted or 30 substituted phenyl or phenoxy, as mentioned above in particular;

35 phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, $\text{C}_1\text{-C}_4\text{-alkyl}$, $\text{C}_1\text{-C}_4\text{-haloalkyl}$, $\text{C}_1\text{-C}_4\text{-alkoxy}$, $\text{C}_1\text{-C}_4\text{-haloalkoxy}$, phenoxy, $\text{C}_1\text{-C}_4\text{-alkylthio}$, $\text{C}_1\text{-C}_4\text{-alkylamino}$ [sic] or $\text{C}_1\text{-C}_4\text{-dialkylamino}$, as mentioned in particular for R^7 and R^4 ;

40 45 a five- or six-membered heteroaromatic moiety which contains one to three nitrogen atoms and/or one sulfur or oxygen atom and which can carry one to four halogen atoms and/or one or two of the following radicals: $\text{C}_1\text{-C}_4\text{-alkyl}$, $\text{C}_1\text{-C}_4\text{-haloalkyl}$, $\text{C}_1\text{-C}_4\text{-alkoxy}$, $\text{C}_1\text{-C}_4\text{-haloalkoxy}$, $\text{C}_1\text{-C}_4\text{-alkylthio}$, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: $\text{C}_1\text{-C}_4\text{-alkyl}$,

16

C_1-C_4 -haloalkyl, C_1-C_4 -alkoxy, C_1-C_4 -haloalkoxy and/or C_1-C_4 -alkylthio, as mentioned for R^4 in particular;

Y sulfur, oxygen or a single bond;

5

Z sulfur, oxygen, $-SO^-$, $-SO_2^-$ or a single bond.

Particularly preferred compounds of the formula I, both as pure enantiomers and pure diastereomers or as mixture thereof, are

10 those in which the substituents have the following meanings:

R^2 C_1-C_4 -alkyl, C_1-C_4 -alkoxy

X nitrogen or CR^{14} , where

15

R^{14} is hydrogen or alkyl, or CR^{14} forms together with CR^3 a 4- or 5-membered alkylene or alkenylene ring such as $-CH_2-CH_2-CH_2-$, $-CH=CH-CH_2-$, in which in each case a methylene group can be replaced by oxygen or sulfur, such as $-CH_2-CH_2-O-$, $-CH=CH-O-$,

20

$-CH_2-CH_2-CH_2-O-$, $-CH=CH-CH_2O-$, in particular hydrogen, $-CH_2-CH_2-O-$, $-CH(CH_3)-CH(CH_3)-O-$, $-C(CH_3)=C(CH_3)-O-$, $-CH=C(CH_3)-O-$ or $-C(CH_3)=C(CH_3)-S$;

R^3 the C_1-C_4 -alkyl, C_1-C_4 -alkoxy, C_1-C_4 -alkylthio groups

25

mentioned for R^1 , or is linked to R^{14} as mentioned above to give a 5- or 6-membered ring;

R^4 and R^5 phenyl (identical or different) which can be substituted by one or more, e.g. one to three, of the

30

following radicals: halogen, nitro, hydroxyl, C_1-C_4 -alkyl, C_1-C_4 -alkoxy, C_1-C_4 -alkylthio or

R^4 and R^5 are phenyl groups which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or

35

ethenylene group, an oxygen or sulfur atom or an SO_2 , NH or N-alkyl group; or

R^4 and R^5 are C_3-C_7 -cycloalkyl;

40

R^6 C_1-C_8 -alkyl, C_3-C_6 -alkenyl or C_3-C_8 -cycloalkyl, it being possible for these radicals in each case to be substituted one or more times by: halogen, hydroxyl, nitro, cyano, C_1-C_4 -alkoxy, C_3-C_6 -alkenyloxy, C_1-C_4 -alkylthio;

45

phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, phenoxy, C₁-C₄-alkylthio, C₁-C₄-akylamino [sic] or C₁-C₄-dialkylamino;

a five- or six-membered heteroaromatic moiety which contains a nitrogen atom and/or a sulfur or oxygen atom and which can carry one to four halogen atoms and/or one or two of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and/or C₁-C₄-alkylthio;

Y sulfur, oxygen or a single bond;

Z sulfur, oxygen, -SO-, -SO₂- or a single bond.

The compounds of the present invention provide a novel therapeutic potential for the treatment of hypertension, pulmonary hypertension, myocardial infarct, angina pectoris, acute kidney failure, renal insufficiency, cerebral vasospasms, cerebral ischemia, subarachnoid hemorrhages, migraine, asthma, atherosclerosis, endotoxic shock, endotoxin-induced organ failure, intravascular coagulation, restenosis after angioplasty, benign prostate hyperplasia, or hypertension or kidney failure caused by ischemia or intoxication.

The good effect of the compounds can be shown in the following tests:

Receptor binding studies

Cloned human ET_A receptor-expressing CHO cells and guinea pig cerebellar membranes with > 60 % ET_B compared with ET_A receptors were used for binding studies.

40 Membrane preparation

The ET_A receptor-expressing CHO cells were grown in F₁₂ medium containing 10 % fetal calf serum, 1 % glutamine, 100 U/ml penicillin and 0.2 % streptomycin (Gibco BRL, Gaithersburg, MD, USA). After 48 h, the cells were washed with PBS and incubated with 0.05 % trypsin-containing PBS for 5 min. Neutralization was then carried out with F₁₂ medium, and the cells were collected by cen-

trifugation at 300 x g. To lyze the cells, the pellet was briefly washed with lysis buffer (5 mM Tris-HCl, pH 7.4 with 10 % glycerol) and then incubated at a concentration of 10^7 cells/ml of lysis buffer at 4°C for 30 min. The membranes were centrifuged at 5 20,000 x g for 10 min, and the pellet was stored in liquid nitrogen.

Guinea pig cerebella were homogenized in a Potter-Elvejhem homogenizer and [lacuna] obtained by differential centrifugation 10 at 1000 x g for 10 min and repeated centrifugation of the supernatant at 20,000 x g for 10 min.

Binding assays

15 For the ET_A and ET_B receptor binding assay, the membranes were suspended in incubation buffer (50 mM Tris-HCl, pH 7.4 with 5 mM MnCl₂, 40 µg/ml bacitracin and 0.2 % BSA) at a concentration of 50 µg of protein per assay mixture and incubated with 25 pM [125I]-ET₁ [sic] (ET_A receptor assay) or 25 pM [125I]-RZ₃ [sic] 20 (ET_B receptor assay) in the presence and absence of test substance at 25°C. The nonspecific binding was determined using 10^{-7} M ET₁. After 30 min, the free and bound radioligand were separated by filtration through GF/B glass fiber filters (Whatman, England) on a Skatron cell collector (Skatron, Lier, Norway) and the filters 25 were washed with ice-cold Tris-HCl buffer, pH 7.4 with 0.2 % BSA. The radioactivity collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter.

Functional in vitro assay system to look for endothelin receptor 30 (subtype A) antagonists

This assay system is a functional, cell-based assay for endothelin receptors. When certain cells are stimulated with endothelin 1 (ET1) they show an increase in the intracellular calcium concentration. This increase can be measured in intact cells loaded 35 with calcium-sensitive dyes.

1-Fibroblasts which had been isolated from rats and in which an endogenous endothelin receptor of the A subtype had been detected 40 were loaded with the fluorescent dye Fura 2-an as follows: after trypsinization, the cells were resuspended in buffer A (120 mM NaCl, 5 mM KCl, 1.5 mM MgCl₂, 1 mM CaCl₂, 25 mM HEPES, 10 mM glucose, pH 7.4) to a density of 2×10^6 /ml and incubated with Fura 2-am (2 µM), Pluronics F-127 (0.04 %) und DMSO (0.2 %) at 45 37°C in the dark for 30 min. The cells were then washed twice with buffer A and resuspended at 2×10^6 /ml.

The fluorescence signal from 2×10^5 cells per ml with Ex/Em 380/510 was recorded continuously at 30°C. To the cells were the test substances and, after an incubation time of 3 min, ET1 was the maximum change in the fluorescence determined. [sic] The 5 response of the cells to ET1 without previous addition of a test substance was used as control and was set equal to 100 %.

Testing of ET antagonists in vivo

10 Male SD rats weighting 250-300 g were anesthetized with amobarbital, artificially ventilated, vagotomized and pithed. The carotid artery and jugular vein were catheterized.

15 In control animals, intravenous administration of 1 µg/kg ET1 leads to a distinct rise in blood pressure which persists for a lengthy period.

20 The test animals received an i.v. injection of the test compounds (1 ml/kg) 5 min before the administration of ET1. To determine the ET-antagonistic properties, the rise in blood pressure in the test animals was compared with that in the control animals.

Endothelin-1-induced sudden death in mice

25 The principle of the test is the inhibition of the sudden heart death caused in mice by endothelin, which is probably induced by constriction of the coronary vessels, by pretreatment with endothelin receptor antagonists. Intravenous injection of 10 nmol/kg endothelin in a volume of 5 ml/kg of body weight results in death 30 of the animals within a few minutes.

35 The lethal endothelin-1 dose is checked in each case on a small group of animals. If the test substance is administered intravenously, the endothelin-1 injection which was lethal in the reference group usually takes place 5 min thereafter. With other modes of administration, the times before administration are extended, where appropriate up to several hours.

40 The survival rate is recorded, and effective doses which protect 50 % of the animals (ED 50) from endothelin-induced heart death for 24 h or longer are determined.

Functional test on vessels for endothelin receptor antagonists

20

Segments of rabbit aorta are, after an initial tension of 2 g and a relaxation time of 1 h in Krebs-Henseleit solution at 37°C and pH 7.3-7.4, first induced to contract with K⁺. After washing out, an endothelin dose-effect plot up to the maximum is constructed.

5

Potential endothelin antagonists are administered to other preparations of the same vessel 15 min before starting the endothelin dose-effect plot. The effects of the endothelin are calibrated as a % of the K⁺-induced contraction. Effective endothelin antagonists result in a shift to the right in the endothelin dose-effect plot.

The compounds according to the invention can be administered orally or parenterally (subcutaneously, intravenously, intra-15 muscularly, intraperitoneally [sic]) in a conventional way. Administration can also take place with vapors or sprays through the nasopharyngeal space.

The dosage depends on the age, condition and weight of the 20 patient and on the mode of administration. The daily dose of active substance is, as a rule, about 0.5-50 mg/kg of body weight on oral administration and about 0.1-10 mg/kg of body weight on parenteral administration.

25 The novel compounds can be used in conventional solid or liquid pharmaceutical forms, eg. as uncoated or (film-)coated tablets, capsules, powders, granules, suppositories, solutions, ointments, creams or sprays. These are produced in a conventional way. The active substances can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, release-slowning agents, antioxidants and/or propellant gases (cf. H. Sucker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1991). The administration forms obtained in this way 35 normally contain from 0.1 to 90 % by weight of the active substance.

Synthesis examples

40

Example 1

Methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate

5 g (19.6 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate were 45 dissolved in 50 ml of absolute methanol and, at 0°C, 0.1 ml of boron trifluoride etherate was added. The mixture was stirred at 0°C for 2 h and at room temperature for a further 12 h. The sol-

21

vent was distilled out, the residue was taken up in ethyl acetate, washed with sodium bicarbonate solution and water and dried over magnesium sulfate. After removal of the solvent by distillation there remained 5.5 g (88 %) of a pale yellow oil.

5

Example 2

Methyl 2-hydroxy-3-phenoxy-3,3-diphenylpropionate

5 g (19.6 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate and 10 5.6 g (60 mmol) of phenol were heated together at 100°C for 6 h. Removal of the excess phenol by distillation under high vacuum and purification of the residue by chromatography on silica gel with hexane/ethyl acetate mixtures resulted in 4.9 g (77 %) of a pale yellow oil.

15

Example 3

Methyl 2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionate

20 2.86 g (10 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 40 ml of dimethylformamide, and 0.3 g (12 mmol) of sodium hydride was added. The mixture was stirred for 1 h and then 2.2 g (10 mmol) of 4,6-dimethoxy-2-methysulfonylpromidine were added. After stirring at room temperature for 24 h, cautious hydrolysis was carried out with 10 ml of water, the pH was adjusted to 5 with acetic acid, and the solvent was removed by distillation under high vacuum. The residue was taken up in 100 ml of ethyl acetate, washed with water and dried over magnesium sulfate, and the solvent was distilled out. The 25 residue was mixed with 10 ml of ether, and the resulting precipitate was filtered off with suction. After drying, 3.48 g (82 %) of a white powder remained.

Melting point 81°C.

35

Example 4
2-(4,6-Dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid

2.12 g (5 mmol) of methyl 2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml of dioxane, 10 ml of 1 N KOH solution were added, and the mixture was stirred at 100°C for 3 h. The solution was diluted with 300 ml of water and extracted with ethyl acetate to remove unreacted ester. The aqueous phase was then adjusted to pH 1-2 with dilute 40 hydrochloric acid and extracted with ethyl acetate. After drying over magnesium sulfate and removal of the solvent by distillation, the residue was mixed with an ether/hexane mixture, and the 45

precipitate which formed was filtered off with suction. After drying, 1.85 g (90 %) of a white powder remained.
Melting point 167°C

5 Example 5

2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl sodium propionate [sic]

1.68 g (4 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methoxy-
10 3,3-diphenylpropionic acid are dissolved in 4 ml of 1N NaOH + 100 ml of water. The solution is freeze-dried, and the sodium salt of the carboxylic acid used is obtained quantitatively.

15 Example 6

10 g (34.9 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml each of methanol and glacial acetic acid, 1 ml of RuO(OH)₂ in dioxane was added, and hydrogenation was carried out with H₂ in an autoclave at 100°C under
20 100 bar for 30 h. The catalyst was filtered off, the mixture was concentrated, mixed with ether and washed with NaCl solution, and the organic phase was dried and concentrated. 10.1 g of methyl 3,3-dicyclohexyl-2-hydroxy-3-methoxypropionate were obtained as an oil.

25

Example 7

Methyl 2-[(4,6-dimethoxypyrimidin-2-yl)thio]-3-methoxy-3,3-diphenylpropionate [sic]

30 7.16 g (25 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml of dichloromethane, 3 g (30 mmol) of triethylamine were added, and 3.2 g (28 mmol) of methanesulfonyl chloride were added dropwise while stirring. The mixture was stirred at room temperature for 2 h, washed with water, dried
35 over magnesium sulfate and concentrated under reduced pressure. The residue was taken up in DMF and added dropwise at 0°C to a suspension of 12.9 g (75 mmol) of 4,6-dimethoxypyrimidine-2-thiol and 8.4 g (100 mmol) of sodium bicarbonate in 100 ml of DMF. After stirring at room temperature for 2 h and at 60°C for a
40 further 2 h, the mixture was poured into 1 liter of ice-water, and the resulting precipitate was filtered off with suction. After drying, 3.19 g (29 %) of a white powder remained.

Example 8

Methyl 2-hydroxy-3,3-diphenylbutyrate

1.5 g (5.9 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate dissolved in 10 ml of absolute ether were added dropwise to a cuprate solution which had been prepared from 635 mg (7 mmol) of copper(I) cyanide dissolved in 10 ml of absolute ether and 8.14 ml (13 mmol) of a 1.6 normal methyllithium solution and had been cooled to -78°C. The solution was stirred at -78°C for 1 h and then allowed to warm to room temperature. It was subsequently diluted with 100 ml of ether and 100 ml of water, and the ether phase was washed with dilute citric acid and with sodium bicarbonate solution and dried over magnesium sulfate. The crude product was purified by chromatography on silica gel with cyclohexane/ethyl acetate mixtures to result in 250 mg (16 %) of a pale yellow oil.

Example 9

2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid

91.11 g (0.5 mol) of benzophenone and 45.92 g (0.85 mol) of sodium methoxide were suspended in 150 ml of methyl tert-butyl ether (MTB) at room temperature. After cooling to -10°C, 92.24 g (0.85 mol) of methyl chloroacetate were added in such a way that the internal temperature rose to 40°C while continuing to cool in a bath at -10°C. The mixture was then stirred without cooling at the autogenous temperature for one hour. After addition of 250 ml of water and brief stirring, the aqueous phase was separated off. The MTB phase was washed with 250 ml of dilute sodium chloride solution. After the solvent had been changed to methanol (250 ml), a solution of 1 g of p-toluenesulfonic acid in 10 ml of methanol was added at room temperature. The mixture was stirred at autogenous temperature for one hour and then heated to reflux. While distilling out the methanol, 400 g of a 10 % strength sodium hydroxide solution was added dropwise, and finally 60 ml of water were added. The methanol was distilled out until the bottom temperature reached 97°C. After cooling to 55°C, 190 ml of MTB were added and the mixture was acidified to pH 2 with about 77 ml of concentrated HCl. After cooling to room temperature, the aqueous phase was separated off and the organic phase was concentrated by distilling out 60 ml of MtB [sic]. The product was crystallized by adding 500 ml of heptane and slowly cooling to room temperature. The coarsely crystalline solid was filtered off with suction, washed with heptane and dried to constant weight in a vacuum oven at 40°C.

Yield: 108.9 g (80 %), HPLC > 99.5 % area.

Example 10

S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (racemate resolution with L-proline methyl ester)

5 148.8 g of a 30 % strength methanolic sodium methanolate solution (0.826 mol) were added dropwise to 240 g of a 57 % strength methanolic L-proline methyl ester hydrochloride solution (0.826 mol) at room temperature, and 2.4 l of MTB and 225 g (0.826 mol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid 10 were added. After 2680 ml of MTB/methanol mixture had been distilled out with simultaneous dropwise addition of 2.4 l of MTB, the mixture was slowly cooled to room temperature, the crystals (R-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid x L-proline methyl ester) were filtered off with suction, and the solid was 15 washed with 150 ml of MTB. The filtrate was concentrated by distilling out 1.5 l of MTB, and 1.0 l of water was added. The pH was adjusted to 1.2 with concentrated hydrochloric acid at room temperature and, after stirring and phase separation, the aqueous phase was separated off and extracted with 0.4 l of MTB. The combined organic phases were extracted with 0.4 l of water. The residue after the MTB had been stripped off was dissolved in 650 ml of toluene under reflux, and the product was crystallized by seeding and slow cooling. Filtration with suction, washing with toluene and drying in a vacuum oven resulted in 78.7 g of 25 S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid (yield 35 % based on the racemate).

Chiral HPLC: 100 % pure

HPLC: 99.8 %

30 Example 11

S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (racemate resolution with (S)-1-(4-nitrophenyl)ethylamine)

30.5 g (0.184 mol) of (S)-1-(4-nitrophenyl)ethylamine were added 35 to 100 g (0.368 mol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid in 750 ml of acetone and 750 ml of MTB under reflux, the mixture was seeded, boiled under reflux for one hour and slowly cooled to room temperature for crystallization. The crystals (S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid x (S)-1-(4-nitrophenyl)ethylamine) were filtered off with suction and washed 40 with MTB. The residue was suspended in 500 ml of water and 350 ml of MTB and then the pH was adjusted to 1.2 with concentrated hydrochloric acid at room temperature, and, after stirring and phase separation, the aqueous phase was separated off and extracted with 150 ml of MTB. The combined organic phases were extracted with 100 ml of water. 370 ml of MTB were distilled out 45 and then 390 ml of n-heptane were added under reflux, and the

mixture was slowly cooled to room temperature while the product crystallized. Filtration with suction, washing with n-heptane and drying in a vacuum oven resulted in 35.0 g of S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid (yield 35 % based on the reactant).

Chiral HPLC: 100 % pure

HPLC: 99.8 %

Example 12

10 Benzyl 3-methoxy-2-(4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionate

24.48 g (90 mmol) of 3-methoxy-3,3-diphenyl-2-hydroxypropionic acid were dissolved in 150 ml of DMF, and 13.7 g (99 mmol) of 15 potassium carbonate were added. The suspension was stirred at room temperature for 30 min. Then 10.7 ml (90 mmol) of benzyl bromide were added dropwise over the course of 5 min, and the mixture was stirred for 1 h, during which the temperature rose to 32°C.

20

To this mixture were successively added 24.84 g (180 mmol) of K_2CO_3 and 20.52 g (90 mmol) of 2-methanesulfonyl-4-methoxy-6,7-dihydro-5H-cyclopentapyridine [sic], and the mixture was stirred at 80°C for 3 h.

25

For workup, the contents of the flask were diluted with about 600 ml of H_2O and cautiously acidified with concentrated HCl, and 250 ml of ethyl acetate were added. 31.4 g of pure product precipitated and were filtered off.

30

The ethyl acetate phase was separated from the mother liquor, the aqueous phase was extracted again with ethyl acetate, and the combined organic phases were concentrated. The oily residue (19 g) was purified by chromatography (cyclohexane/ethyl acetate = 9/1) to result in a further 10.5 g of pure product.

Total yield: 41.9 g (82.2 mmol) ≈ 91 %

Melting point 143-147°C

MS: MH^+ = 511

40

Example 13

3-Methoxy-2-(4-methoxy-(6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionic [sic] acid

45 40 g (78.4 mmol) of benzyl 3-methoxy-2-(4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionate were dissolved in 400 ml of ethyl acetate/methanol (4:1), about 500 mg

26

of palladium on active carbon (10 %) were added, and the mixture was exposed to a hydrogen atmosphere until no further gas was taken up. The catalyst was filtered off, the solution was evaporated, and the residue was crystallized from ether.

5

Example 14

Ethyl 2S-3,3-diphenyloxirane-2-carboxylate

2.57 g (10.2 mmol) of ethyl 3,3-diphenylacrylate and 464 mg of 10 4-phenylpyridine N-oxide were dissolved in 24 ml of methylene chloride, and 432 mg (6.5 mol%) of (5,5)-(+)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminomanganese(III) [sic] chloride were added. While cooling in ice, 6.4 ml of a 12 % strength sodium hypochloride [sic] solution were added, and the 15 mixture was stirred while cooling in ice for 30 min and at room temperature overnight. The solution was diluted to 200 ml with water, extracted with ether, dried and evaporated. 2.85 g of a colorless oil were obtained. Purification by NPLC [sic] (cyclohexane:ethyl acetate = 9:1) resulted in 1.12 g of oil with an 20 enantiomer ratio of about 8:1 in favor of the S configuration.

¹H-NMR [CDCl₃],

δ = 1.0 (t, 3H); 3.9 (m, 3H); 7.3 (m, 10H)

25 Example 15

2-Methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidin-4-ol [sic]

46.9 g (330 mmol) of methyl cyclopentanone-2-carboxylate and 53.5 g (192 mmol) of 5-methylisothiourea [sic] sulfate were successively added to 29.6 g (528 mmol) of KOH in 396 ml of methanol, and the mixture was stirred at room temperature overnight, acidified with 1N hydrochloric acid and diluted with water. The crystals which separated out were filtered off with suction and dried. 20 g of crystals were obtained.

35

Example 16

4-Chloro-2-methylsulfanyl-6,7-dihydro-5H-cyclopentapyrimidine

255 ml of phosphorus oxychloride were added to 20 g (110 mmol) of 40 [lacuna], and the mixture was stirred at 80°C for 3 hours. Phosphorus oxychloride was evaporated off, ice was added to the residue, and the crystals which separated out were filtered off with suction. 18.5 g of a brownish solid were obtained.

45

Example 17

4-Methoxy-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine

18.05 g (90 mmol) of 4-chloro-2-methylthio-6,7-dihydro-5H-cyclopentapyrimidine were dissolved in 200 ml of methanol. At 45°C, 16.7 g of sodium methoxide (as 30 % strength solutions [sic] in methanol) were added dropwise, and the mixture was stirred for 2 hours. The solution was evaporated, taken up in ethyl acetate and acidified with dilute hydrochloric acid, and the ethyl acetate extract was evaporated. 15.5 g of an oil remained.

¹H-NMR [DMSO],
δ = 2.1 (quintet, 2H); 2.5 (s, 3H);
2.8 (dt, 4H); 3.9 (s, 3H) ppm

15

Example 18

2-Methylsulfonyl-4-methoxy-6,7-dihydro-5H-cyclopentopyrimidine [sic]

20 15 g (76.2 mmol) of 4-methoxy-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine [sic] were dissolved in 160 ml of glacial acetic acid/methylene chloride (1:1), and 1.3 g of sodium tungstate were added. At 35°C, 17.5 ml (170 ml [sic]) of a 30 % strength H₂O₂ solution were added dropwise. The mixture was then 25 diluted with 500 ml of water and 100 ml of methylene chloride, and the organic phase was separated off, dried and evaporated. 14 g of oil remained and were crystallized from ether.

¹H-NMR [CDCl₃],
30 δ = 2.2 (quintet, 2H); 3.0 (dt., 4H);
3.3 (s, 3H); 4.1 (s, 3H) ppm

Example 19

1-Benzenesulfonyl-3-(4,6-dimethoxy-2-pyrimidinyloxy)-4-methoxy-35 4,4-diphenyl-2-butanone

0.37 g (2.4 mmol) of phenyl methane [sic] sulfone were dissolved in 10 ml of dry THF and then, at -70°C, 2 eq. of butyllithium (2.94 ml; 1.6 molar solution in hexane) were added dropwise. 40 After 1 h at -70°C, 1 g (2.4 mmol) of methyl 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenylpropionate [sic] dissolved in 5 ml of THF was added dropwise. The reaction mixture was then stirred at -70°C for 1 h and at -10°C for 1 h and then warmed to room temperature.

45

For workup, about 10 ml of saturated NH₄Cl solution were added dropwise, thorough extraction with ethyl acetate was carried out, and the combined organic phases [lacuna] with saturated N-Cl [sic] solution and dried over Na₂SO₄. The residue obtained after 5 drying and concentration was purified by chromatography on silica gel (n-heptane/ethyl acetate 15 % → 30 %) and subsequently MPLC on RP silica gel (acetonitrile/H₂O + TFA); 0.3 g of a white amorphous powder was obtained as product.

10 Example 20

3,3-Diphenyloxiram-2-carbonitrile [sic]

3.1 g (54.9 mmol) of sodium methoxide were suspended in 20 ml of dry THF and then, at -10°C, a mixture of 5 g (27.4 mmol) of benzo-15 phenone and 4.2 g (54.9 mmol) of chloroacetonitrile was added dropwise.

The reaction mixture was stirred at -10°C for about 2 h, then poured into water and extracted several times with ethyl acetate.

20 The combined organic phases were dried over Na₂SO₄ and concentrated, and the residue was purified by chromatography on silica gel (n-heptane/ethyl acetate).

Yield: 1.2 g (20 %)

25 ¹H-NMR [CDCl₃],

δ = 3.9 (s, 1H); 7.4-7.5 (m, 10 H) ppm

Example 21

2-Hydroxy-3-methoxy-3,3-diphenylpropionitrile

30

6.5 [lacuna] (29.4 mmol) of 3,3-diphenyloxirane-2-carbonitrile were dissolved in 60 ml of methanol and, at 0°C, about 2 ml of boron trifluoride etherate solution were added. The mixture was stirred further at 0°C for 1 h and then at room temperature over-35 night. For workup it was diluted with diethyl ether and washed with saturated NaCl solution, and the organic phase was dried over Na₂SO₄ and concentrated. The residue comprised 7.3 g of a white amorphous powder which was used directly in the subsequent reactions.

40

¹H-NMR [CDCl₃],

δ = 2.95 (broad s, OH), 3.15 (s, 3H),
5.3 (s, 1H), 7.3-7.5 (m, 10) ppm

Example 22

2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenylpropionitrile

5 7.3 g (28.8 mmol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionitrile were dissolved in 90 ml of DMF, and 4 g (28.8 mmol) of K_2CO_3 and 6.3 g (28 mmol) of 2-methanesulfonyl-4,6-dimethoxypyrimidine were added. The mixture was stirred at room temperature for about 12 h, then poured into water and extracted with ethyl acetate. The combined organic phases were washed again with H_2O , dried and concentrated. The residue obtained in this way was then purified by chromatography on silica gel (n-heptane/ethyl acetate).

Yield: 6.9 g of white amorphous powder

15

FAB-MS: 392 ($M+H^+$)

1H -NMR [CDCl₃],

δ = 3.3 (s, 3H); 4.95 (s, 6H), 5.85 (s, 1H);
6.3 (s, 1H); 7.3-7.5 (m, 10H) ppm

20

Example 23

5-[2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)-propyl]-1H-tetrazole [sic]

25 0.5 g (1.3 mmol) of nitrile was dissolved in 10 ml of toluene, and 85 mg (1.3 mmol) of NaN₃ and 460 mg (1.4 mmol) of Bu₃SnCl were successively added, and then the mixture was refluxed for about 40 h. Cooling was followed by dilution with ethyl acetate and washing with 10 % aqueous KF solution and with NaCl solution.

30 After drying over MgSO₄ and concentration there remained 1.0 g of a yellow oil, which was purified by chromatography on silica gel (n-heptane/ethyl acetate).

Concentration of the fractions resulted in 60 mg of the 1H-tetrazole and 110 mg of the 1-methyltetrazole, each as amorphous white solids.

5-[2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)-propyl]-1H-tetrazole [sic]

40

Electrospray-MS: 435 ($M+H^+$)

1H -NMR (CDCl₃):

δ (ppm) 3.28 (s, 3H), 3.85 (s, 6H), 5.75 (s, 1H), 7.25-7.40 (m, 10H), 7.50 (s, 1H).

45

30

5-[2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)-propyl]-1-methyltetrazole [sic]

Electrospray-MS; 471 (M+H⁺)

5 ¹H-NMR (CDCl₃):

δ (ppm) 3.0 (s, 3H), 3.35 (s, 3H) [sic], 3.80 (s, 6H), 5.75 (s, 1H), 7.30-7.40 (m, 11H).

Example 24

10 2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methylsulfinyl-3,3-diphenylpropionic acid

1.2 g (2.9 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methylsulfonyl-3,3-diphenylpropionic [sic] acid were introduced 15 into 15 ml of glacial acetic acid at 0°C and 294 μl of 30 % strength H₂O₂ were added dropwise. The mixture was stirred at room temperature overnight, poured into water, extracted with CH₂Cl₂ and washed with sodium thiosulfate solution and brine. After drying, 1 g of substance was isolated as a white foam.

20

Example 25

2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methylsulfonyl-3,3-diphenylpropionic acid

25 0.6 g (1.45 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methylsulfonyl-3,3-diphenylpropionic [sic] acid was introduced into 15 ml of glacial acetic acid at room temperature, and 294 μl of 30 % strength H₂O₂ were added dropwise. The mixture was stirred at room temperature overnight, heated at 50°C for a further 3 h, poured 30 into water and washed with sodium thiosulfate solution and brine. After drying, 400 mg were isolated as a white solid.

The compounds listed in Table 1 [sic] can be prepared in a similar way.

35

40

45




Table I

No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m.p. [°C]
I-1	OMe	Phenyl	Methyl	OMe	OMe	CH	0	0	81
I-2	OH	Phenyl	Methyl	OMe	OMe	CH	0	0	167
I-3	OH	Phenyl	CH ₂ -CH ₂ -S-CH ₃	OMe	OMe	CH	0	0	
I-4	OH	Phenyl	Ethyl	OMe	OMe	CH	0	0	81 (decomp.)
I-5	OH	Phenyl	iso-Propyl	OMe	OMe	CH	0	0	182
I-6	OH	Phenyl	Methyl	OMe	OMe	CH	0	S	168
I-7	OH	Phenyl	CH ₂ -CH ₂ -SO ₂ -CH(CH ₃) ₂	OMe	OMe	CH	0	0	
I-8	OH	Phenyl	CH ₂ -CH ₂ -SO ₂ -CH(CH ₃) ₂	OMe	OMe	CH	S	0	
I-9	OH	Phenyl	CH ₂ -CH ₂ -SO ₂ -CH(CH ₃) ₂	OMe	OMe	C-CH(CH ₃) ₂	0	0	
I-10	OH	Phenyl	CH ₂ -CH ₂ -SO ₂ -CH(CH ₃) ₂	OMe	OMe	C-CH(CH ₃) ₃	0	0	
I-11	OH	Phenyl	CH ₂ -CH ₂ -SO ₂ -CH(CH ₃) ₂	OMe	NH-OCH ₃	CH	0	0	
I-12	OH	Phenyl	n-Propyl	OMe	OMe	CH	0	0	174
I-13	OMe	Phenyl	n-Propyl	OMe	OMe	CH	0	0	
I-14	OH	Phenyl	n-Propyl	OEt	OEt	CH	0	0	

No.	R ¹	R ^{4, R⁵}	R ⁶	R ²	R ³	X	Y	Z	m.p. [°C]
I-15	OH	Phenyl	n-Butyl	OMe	OMe	CH	0	0	
I-16	OH	Phenyl	iso-Butyl	OMe	OMe	CH	0	0	
I-17	OH	Phenyl	iso-Butyl	OMe		O-CH ₂ -CH ₂ -C	0	0	
I-18	OH	Phenyl	tert.-Butyl	OMe	OMe	CH	0	0	
I-19	OH	Phenyl	Cyclopropyl	OMe	OMe	CH	0	0	
I-20	OH	Phenyl	Cyclopentyl	OMe	OMe	CH	0	0	
I-21	OH	Phenyl	Cyclohexyl	OMe	OMe	CH	0	0	
I-22	OH	Phenyl	(CH ₃) ₂ C-CH ₂ -CH ₂	OMe	OEt	CH	0	0	
I-23	OH	Phenyl	(CH ₃) ₂ CH-CH ₂ -CH ₂ -CH ₂	OMe	OMe	CH	0	0	173
I-24	OH	Phenyl	HO-CH ₂ -CH ₂	OMe	OMe	CH	0	0	
I-25	OH	Phenyl	HO ₂ C-(CH ₂) ₂ -	OMe	OMe	CH	0	0	
I-26	OH	Phenyl	Cyclopropylmethylene [sic]	OMe	OMe	CH	0	0	115
I-27	OH	Phenyl	H	OMe	OMe	CH	0	0	
I-28	OH	Phenyl	Methyl	OMe	OMe	CH	0	-	
I-29	OH	Phenyl	Phenyl	OMe	OMe	CH	0	0	136
I-30	OH	Phenyl	Phenyl	OMe		O-CH(CH ₃)-CH ₂ -C	0	0	
I-31	OMe	Phenyl	Phenyl	OMe	OMe	CH	0	0	
I-32	OH	Phenyl	4-Isopropyl-Phenyl	OMe	OMe	CH	0	0	
I-33	OH	Phenyl	4-Me-S-Phenyl	OMe	OMe	CH	0	0	
I-34	OH	Phenyl	4-Me-O-Phenyl	OMe	OMe	CH	0	0	
I-35	OH	Phenyl	3-Et-Phenyl	OMe	OMe	CH	0	0	
I-36	OH	Phenyl	2-Me-Phenyl	OMe	OMe	CH	0	0	

No.	R ¹	R ^{4, R⁵}	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
I-37	OH	Phenyl	2-Cl-Phenyl	OMe	OMe	CH	0	0	
I-38	OH	Phenyl	3-Br-Phenyl	OMe	OMe	CH	0	0	
I-39	OH	Phenyl	4-F-Phenyl	OMe	OMe	CH	0	0	
I-40	OH	Phenyl	4-F-Phenyl	OMe	OMe	CH	S	0	
I-41	OH	Phenyl	4-CH ₃ -Phenyl	OMe	OMe	CH	0	0	
I-42	OH	Phenyl	3-NO ₂ -Phenyl	OMe	OMe	CH	0	0	
I-43	OH	Phenyl	2-HO-Phenyl	OMe	OMe	CH	0	0	
I-44	OH	Phenyl	3,4-Dimethoxyphenyl	OMe	OMe	CH	0	0	
I-45	OH	Phenyl	3,4-Dioxymethylenephenoxy [sic]	OMe	OMe	CH	0	0	
I-46	OH	Phenyl	3,4,5-Trimethoxyphenyl	OMe	OMe	CH	0	0	
I-47	OH	Phenyl	Benzyl	OMe	OMe	CH	0	0	
I-48	OH	Phenyl	2-Cl-Benzyl	OMe	OMe	CH	0	0	
I-49	OH	Phenyl	3-Br-Benzyl	OMe	OMe	CH	0	0	
I-50	OH	Phenyl	4-F-Benzyl	OMe	OMe	CH	0	0	
I-51	OH	Phenyl	2-Me-Benzyl	OMe	OMe	CH	0	0	
I-52	OH	Phenyl	2-Me-Benzyl	OMe		O-CH=CH-C	0	0	
I-53	OH	Phenyl	3-Et-Benzyl	OMe	OMe	CH	0	0	
I-54	OH	Phenyl	4-iso-Propyl-Benzyl	OMe	OMe	CH	0	0	
I-55	OH	Phenyl	4-NO ₂ -Propyl-Benzyl	OMe	OMe	CH	0	0	
I-56	OH	Phenyl	2-Me-5-Propyl-Benzyl	OMe	OMe	CH	0	0	
I-57	OH	Phenyl	2-Me-5-Propyl-Benzyl	OEt	OEt	CH	0	0	
I-58	OH	Phenyl	4-Me-2-Propyl-Benzyl	OMe	OMe	CH	0	0	

No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
I-59	OH	Phenyl	3,4-Dioxomethylenebenzyl [sic]	OMe	OMe	CH	0	0	
I-60	OH	4-F-Phenyl	Methyl	OMe	OMe	CH	0	0	163-165 (decomp.)
I-61	OMe	4-F-Phenyl	Methyl	OMe	OMe	CH	0	0	
I-62	OH	4-Cl-Phenyl	Methyl	OMe	OMe	CH	0	0	
I-63	OH	4-Me-O-Phenyl	Methyl	OMe	OMe	CH	0	0	
I-64	OH	4-Me-O-Phenyl	Ethyl	OMe	OMe	CH	0	0	
I-65	OH	4-Me-Phenyl	Methyl	OMe	OMe	CH	0	0	
I-66	OH	4-Me-Phenyl	Methyl	OMe	OMe	O-CH ₂ -CH ₂ -C	0	0	
I-67	OH	3-CF ₃ -Phenyl	n-Propyl	OMe	OMe	CH	0	0	
I-68	OH	3-CF ₃ -Phenyl	n-Propyl	OMe	O-CH(CH ₃)-CH ₂ -C	0	0		
I-69	OH	4-NO ₂ -Phenyl	Methyl	OMe	OMe	CH	0	0	
I-70	OH	4-NO ₂ -Phenyl	Methyl	OMe	O-CH=CH-C	0	0		
I-71	OH	3-Cl-Phenyl	Ethyl	OMe	OMe	CH	0	0	
I-72	OH	2-F-Phenyl	Methyl	OMe	OMe	CH	0	0	193-194 (decomp.)
I-73	OH	2-F-Phenyl	Methyl	OMe	OMe	CH	S	0	
I-74	OH	2-Me-O-Phenyl	Methyl	OMe	OMe	CH	0	0	
I-75	OH	2-Me-O-Phenyl	Methyl	OMe	OMe	CH	0	S	
I-76	OH	3,4-Dimethoxyphenyl	Methyl	OMe	OMe	CH	0	0	
I-77	OH	3,4-Dioxomethylenebenzyl [sic]	Methyl	OMe	OMe	CH	0	0	
I-78	OH	p-CF ₃ -Phenyl	Methyl	OMe	OMe	CH	0	0	

No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
I-79	OH	Phenyl	Methyl	OMe	OEt	CH	0	0	
I-80	OMe	Phenyl	Methyl	OMe	OEt	CH	S	0	
I-81	OH	Phenyl	Ethyl	OMe	NH-OMe	CH	0	0	
I-82	OH	p-Me-O-Phenyl	n-Propyl	OMe	OCF ₃	CH	0	0	
I-83	OH	Phenyl	Methyl	OMe	CF ₃	CH	0	0	
I-84	OH	Phenyl	Methyl	OMe	CF ₃	N	0	0	
I-85	OH	3,4-Dimethoxyphenyl	Benzyl	Me	Me		0	0	
I-86	OH	3,4-Dimethoxyphenyl	Methyl	OMe	O-CH ₂ -CH ₂ -C		0	0	
I-87	OH	Phenyl	Methyl	OMe	O-CH ₂ -CH ₂ -C		0	0	126 (decomp.)
I-88	OH	Phenyl	Methyl	OMe	O-CH(CH ₃)-CH ₂ -C		0	0	
I-89	OH	Phenyl	Methyl	OMe	N(CH ₃)-CH=CH-C		0	0	118
I-90	OH	Phenyl	Methyl	OMe	S-C(CH ₃)=C(CH ₃)-C		0	0	
I-91	OH	Phenyl	Methyl	OMe	O-C(CH ₃)=CH-C		0	0	
I-92	OH	Phenyl	Methyl	Me	O-C(CH ₃)=CH-C		0	0	
I-93	OH	Phenyl	Methyl	Me	O-CH=CH-C		0	0	
I-94	OH	4-F-phenyl	Methyl	Me	S-CH=CH-C		0	0	
I-95	OH	4-F-phenyl	H	OMe	OMe	CH	0	0	
I-96	OH	Phenyl	Methyl	OMe	CH ₂ -CH ₂ -CH ₂ -C		0	0	149-151 (decomp.)
I-97	OH	Phenyl	Methyl	Methyl	CH ₂ -CH ₂ -CH ₂ -C		0	0	157 (decomp.)
I-98	OH	Phenyl	Methyl	Ethyl	CH ₂ -CH ₂ -CH ₂ -CH ₂ -C		0	0	
I-99	OH	Phenyl	Methyl	OMe	CH ₂ -CH ₂ -CH ₂ -CH ₂ -C		0	0	
I-100	OH	Phenyl	Methyl	Me	Me	CH	0	0	

No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
I-101	OH	Phenyl	Methyl	Et	Et	CH	0	0	
I-102	OH	Phenyl	Methyl	Me	Me	C-CH ₃	0	0	
I-103	OH	Phenyl	Methyl	OMe	Me	CH	0	0	
I-104	OH	Cyclohexyl	Methyl	OMe	OMe	CH	0	0	
I-105	OH	Cyclohexyl	Methyl	OMe		CH ₂ -CH ₂ -CH ₂ -C	0	0	
I-106	OH	Phenyl	Methyl	OCH ₃	OCH ₃	CH	S	S	
I-107	OH	Phenyl	Methyl	OCH ₃	OCH ₃	CH	0	S	134
I-108	OCH ₃	Phenyl	Methyl	OCH ₃	OCH ₃	CH	S	S	
I-109	OH	Phenyl	Methyl	OCH ₃	OCH ₃	CH	0	0	
I-110	OCH ₃	2-Fluorophenyl	Methyl	OCH ₃	OCH ₃	CH	0	0	
I-111	OC ₂ H ₅	3-Chlorophenyl	Methyl	OCH ₃	OCH ₃	N	0	0	
I-112	ON(CH ₃) ₂	4-Bromophenyl	Methyl	CF ₃	CF ₃	CH	S	O	
I-113	O-CH ₂ -C=CH	Phenyl	Ethyl	OCH ₃	CF ₃	CH	0	0	
I-114	OH	Phenyl	Propyl	OCH ₃	OCF ₃	CH	0	S	
I-115	OCH ₃	Phenyl	i-Propyl	OCH ₃	CH ₃	CH	0	0	
I-116	OC ₂ H ₅	Phenyl	s-Butyl	OCH ₃	Cl	CH	S	O	
I-117	ON(CH ₃) ₂	2-Methylphenyl	Methyl	OCH ₃	OCH ₃	CH	0	0	
I-118	ON(CH ₃) ₂	3-Methoxyphenyl	Methyl	OCH ₃	OCH ₃	CH	0	0	
I-119	ON=C(CH ₃) ₂	4-Nitrophenyl	Methyl	OCH ₃	OCH ₃	CH	0	0	
I-120	ON(CH ₃) ₂	Phenyl	1-Phenylpropyn-3-yl	OCH ₃	OCF ₃	N	0	S	
I-121	ON=C(CH ₃) ₂	2-Hydroxyphenyl	Methyl	OCH ₃	CH ₃	N	0	0	
I-122	ONSO ₂ C ₆ H ₅	3-Trifluoromethylphenyl	Methyl	OCH ₃	Cl	N	0	0	

No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
I-123	NHPhenyl	4-Dimethylaminophenyl	Methyl	OCH ₃	OCH ₃	CH		S	0
I-124	OC ₂ H ₅	Phenyl	Trifluoroethyl	CH ₃	CH ₃	CH		0	0
I-125	ON(CH ₃) ₂	Phenyl	Benzyl	Cl	Cl	CH		0	0
I-126	ON(CH ₃) ₂	Phenyl	2-Methoxyethyl	OCH ₃	-O-CH ₂ -CH ₂ -		S	0	
I-127	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH		0	0
I-128	OH	Phenyl	Phenyl	OCH ₃	-O-CH ₂ -CH ₂ -		0	0	
I-129	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	N	0	0	
I-130	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	S	0	
I-131	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	S	S	
I-132	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	O	S	
I-133	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	0	0	
I-134	OH	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	0	0	
I-135	OH	-CH ₂ -S-	Phenyl	Phenyl	Phenyl	OCH ₃	CH	0	0
I-136	OH	Phenyl	2-Thiazolyl	OCH ₃	OCH ₃	CH	0	0	
I-137	OCH ₃	2-Fluorophenyl	Phenyl	OCH ₃	OCH ₃	CH	0	0	
I-138	OC ₂ H ₅	3-Chlorophenyl	Phenyl	OCH ₃	OCH ₃	N	0	0	
I-139	ON(CH ₃) ₂	4-Bromophenyl	Phenyl	CF ₃	CF ₃	CH	0	0	
I-140	O-CH ₂ =CH [sic]	Phenyl	2-Fluorophenyl	OCH ₃	CF ₃	CH	0	0	
I-141	OH	Phenyl	3-Chlorophenyl	OCH ₃	OCF ₃	CH	0	S	
I-142	OCH ₃	Phenyl	4-Bromophenyl	OCH ₃	CH ₃	CH	0	0	
I-143	OC ₂ H ₅	Phenyl	4-Thiazolyl	OCH ₃	Cl	CH	S	0	
I-144	ON(CH ₃) ₂	2-Methylphenyl	Phenyl	OCH ₃	OCH ₃	CH	0	0	

No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
I-145	ON=C(CH ₃) ₂	3-Methoxyphenyl	Phenyl	OCH ₃	OCH ₃	CH	0	0	
I-146	OH	Phenyl	Methyl	OCH ₃	-CH ₂ CH ₂ CH ₂ C		0	0	
I-147	OH	4-Fluorophenyl	Methyl	OCH ₃	OCH ₃	CH	0	0	168 (decomp.)
I-148	OH	4-Fluorophenyl	Methyl	OCH ₃	-CH ₂ CH ₂ CH ₂ C		0	0	
I-149	NH-SO ₂ -C ₆ H ₅	4-Nitrophenyl	Phenyl	OCH ₃	OCH ₃	CH	0	0	
I-150	OCH ₃	Phenyl	3-Imidazolyl	OCH ₃	-O-CH ₂ -CH ₂		0	0	
I-151	OC ₂ H ₅	Phenyl	4-Imidazolyl	OCH ₃	CF ₃	N	S	0	
I-152	ON(CH ₃) ₂	Phenyl	2-Pyrazolyl	OCH ₃	OCF ₃	N	0	S	
I-153	ON=C(CH ₃) ₂	2-Hydroxyphenyl	Phenyl	OCH ₃	CH ₃	N	0	0	
I-154	NH-SO ₂ -C ₆ H ₅	3-Trifluoromethylphenyl	Phenyl	OCH ₃	Cl	N	0	0	
I-155	NHPhenyl	4-Dimethylaminophenyl	Phenyl	OCH ₃	OCH ₃	CH	S	0	
I-156	ONa	Phenyl	Phenyl	OCH ₃	OCH ₃	CH	S	S	
I-157	O-CH ₂ C≡C	Phenyl	Phenyl	OCH ₃	OCH ₃	N	S	S	
I-158	OH	Phenyl	Phenyl	CF ₃	CF ₃	CH	0	S	
I-159	OCH ₃	Phenyl	Phenyl	OCF ₃	OCF ₃	CH	0	0	
I-160	OC ₂ H ₅	Phenyl	2-Dimethylaminophenyl	CH ₃	CH ₃	CH	0	0	
I-161	ON(CH ₃) ₂	Phenyl	3-Hydroxyphenyl	Cl	Cl	CH	0	0	
I-162	ON=C(CH ₃) ₂	Phenyl	4-Trifluoromethylphenyl	OCH ₃	-O-CH ₂ -CH ₂ -		S	0	
I-163	NH-SO ₂ -C ₆ H ₅	Phenyl	2-Oxazolyl	OCH ₃	CF ₃	N	S	S	
I-164	OH	Phenyl	Methyl	CH ₃	CH ₃	CH	0	0	
I-165	OH	Cyclohexyl	Methyl	OCH ₃	OCH ₃	CH	0	0	
I-166	OH	Cyclohexyl	Methyl	OCH ₃	CH ₂ -CH ₂ CH ₂ C		0	0	

No.	R ¹	R ⁴ , R ⁵	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
I-167	OH	Phenyl	Methyl	N(CH ₃) ₂	CH		0	0	
I-168	OH	Phenyl	Methyl	OCH ₃	CH		0	SO ₂	
I-169	OH	Phenyl	Methyl	OCH ₃	OCH ₃		0	SO ₂	
I-170	OH	3-F-Phenyl	Me	OMe	OMe	CH	0	0	
I-171	OH	3-F-Phenyl	Me	OMe		CH ₂ CH ₂ CH ₂ -C	0	0	
I-172	OH	4-F-Phenyl	Me	OMe		CH ₂ CH ₂ -CH ₂ -C	0	0	142-143
I-173	OH	3-MeO-Phenyl	Me	OMe		CH ₂ CH ₂ -CH ₂ -C	0	0	191°C
I-174	OH	3-MeO-Phenyl	Me	OMe	OMe	CH	0	0	158-161
I-175	OH	3-MeO-Phenyl	Et	OMe		CH ₂ CH ₂ -CH ₂ -C	0	0	(decomp.)
I-176	OH	Phenyl	HO-CH ₂ -CH ₂	OMe		CH ₂ CH ₂ -CH ₂ -C	0	0	
I-177	OH	Phenyl	Me	NMe ₂	N		0	0	181
I-178	OH	Phenyl	Me	OMe	OMe	N	0	0	
I-179	OH								
I-180	NH-SO ₂ -Phenyl	Phenyl	Me	OMe	OMe	CH	0	0	
I-181	NH-SO ₂ -Me	Phenyl	Me	OMe	OMe	CH	0	0	
I-182	CH ₂ -SO ₂ -Phenyl	Phenyl	Me	OMe	OMe	CH	0	0	
I-183	CH ₂ -SO ₂ -Me	Phenyl	Me	OMe	OMe	CH	0	0	
I-184	-CN	Phenyl	Me	OMe	OMe	CH	0	0	
I-185	Tetrazole [sic]	Phenyl	Me	OMe	OMe	CH	0	0	
I-186	NH-SO ₂ -Phenyl	Phenyl	Me	OMe	OMe	CH	0	0	167

No.	R ¹	R ^{4, R⁵}	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
I-187	N-Methyltetrazole [sic]	Phenyl	Me	OMe	OMe	CH	0	0	
I-188	ONa	Phenyl	Me	OMe	-O-CH ₂ -CH ₂ -C-	0	0	122-139 (decomp.)	
I-189	OH	o-F-Phenyl	Me	OMe	-O-CH ₂ -CH ₂ -C-	0	0	140-144 (decomp.)	
I-190	OH	m-Me-Phenyl	Me	OMe	OMe	CH	0	0	169-177
I-191	OH	m-Me-Phenyl	Me	OMe	-O-CH ₂ -CH ₂ -C-	0	0	119-135 (decomp.)	
I-192	OH	p-F-Phenyl	Me	OMe	Me	CH	0	0	137-140 (decomp.)
I-193	OH	m-F-Phenyl	Me	Me	-O-CH ₂ -CH ₂ -C-	0	0	150-152	
I-194	OH	p-F-Phenyl	Me	Me	-O-CH ₂ -CH ₂ -C-	0	0	169-170	




Table II

No.	R ¹	A	R ⁶	R ²	R ³	X	Y/Z	m.p. [°C]
II-1	OH	Bond	Methyl	OMe	OMe	CH	0	96-98
II-2	OH	CH ₂	Methyl	OMe	OMe	CH	0	0
II-3	OH	CH ₂ -CH ₂	Methyl	OMe	OMe	CH	0	0
II-4	OH	CH=CH	Methyl	OMe	OMe	CH	0	0
II-5	OH	O	Methyl	OMe	OMe	CH	0	0
II-6	OH	S	Methyl	OMe	OMe	CH	0	0
II-7	OH	NH(CH ₃)	Methyl	OMe	OMe	CH	0	0
II-8	OH	Bond	Isopropyl	OMe	OMe	CH	0	137-139
II-9	OH	Bond	p-Isopropylphenyl	OMe	OMe	CH	0	0
II-10	OH	Bond	Benzyl	OMe	OMe	CH	0	0
II-11	OH	CH=CH	Ethyl	OMe	OMe	CH	0	0
II-12	OH	CH=CH	(CH ₃) ₂ -CH ₂ -CH ₂	OMe	OMe	CH	0	0
II-13	OH	CH=CH	Cyclopropylmethylen [sic]	OMe	OMe	CH	0	0
II-14	OH	CH=CH	Methyl	OMe	O-CH ₂ -CH ₂ -C	0	0	
II-15	OH	CH ₂ -CH ₂	Ethyl	OMe	O-CH=CH-C	0	0	

No.	R ¹	A	R ⁶	R ²	R ³	X	Y	Z	m.p.[°C]
II-16	OH	CH ₂ =CH ₂	Methyl	OMe	CH ₂ -CH ₂ -CH ₂ -C		0	0	
II-17	OH	Bond	Methyl	OMe	CH ₂ -CH ₂ -CH ₂ -C		0	0	147

Example 35

Receptor binding data were measured by the binding assay described above for the compounds listed below.

The results are shown in Table 2 [sic].

Table 2 [sic]

10

Receptor binding data (K_i values)

	Compound	ET _A [nM]	ET _B [nM]
15	I-2	6	34
	I-29	86	180
	I-5	12	160
20	I-4	7	2500
	I-87	1	57
	I-89	86	9300
	I-103	0.4	29
25	I-107	3	485
	I-12	19	1700
	I-26	23	2000
	I-23	209	1100
	I-47	150	1500
30	I-60	33	970
	I-96	0.6	56
	II-3	107	7300
35	II-1	28	2300

40

45


Novel carboxylic acid derivatives, their preparation and use

Abstract

5

Carboxylic acid derivatives

10



15

where R-R⁶, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.

20

25

30

35

40

45